FHTX - CIK 0001822462
Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.91M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $30.91M | +36.8% |
| FY 2024 | $22.60M | -33.8% |
| FY 2023 | $34.16M | +77.6% |
| FY 2022 | $19.23M | +1357.8% |
| FY 2021 | $1.32M | +206.7% |
| FY 2020 | $430.00K | - |
Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.91M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Foghorn Therapeutics Inc.'s revenue grew from $430.00K to $30.91M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.